| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787608 | Journal of Thoracic Oncology | 2018 | 27 Pages |
Abstract
The PFS advantage of EGFR-TKI over chemotherapy in advanced EGFR mutant NCLC is not explained by depth of response at 6 or 12 weeks. It should not be used as a surrogate of benefit in future trials or routine clinical decision making.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chee Khoon PhD, Sally MSc, Ian PhD, Yi Long MD, Lecia MD, Rafael MD, Masahiro MD, Tetsuya MD, Rebecca MSc, Lucy MSc, Val MStat, Richard MD, Tony MD, James PhD,